Skip to main content
Terug
SHWGF logo

Shandong Weigao Group Medical Polymer Company Limited

Datakwaliteit: 100%
Overbought
SHWGF
OTC Healthcare Medical - Instruments & Supplies
€ 0,73
€ 0,00 (0,00%)
Marktkapitalisatie: 3,26B
Ook genoteerd als SHWGY OTC
Dagbereik
€ 0,73 € 0,73
52-Weeksbereik
€ 0,66 € 0,76
Volume
4.200
50D / 200D Gem.
€ 0,69 / € 0,73
Vorige Slotkoers
€ 0,73

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 1,6 0,4
P/B 0,1 2,9
ROE % 9,0 3,8
Net Margin % 15,8 3,9
Rev Growth 5Y % 3,0 10,0
D/E 0,2 0,2

Belangrijkste Punten

Revenue grew 3,01% annually over 5 years — modest growth
Net margin of 15,79% shows strong profitability
Debt/Equity of 0,18 — conservative balance sheet
Generating 2,14B in free cash flow
P/E of 1,58 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 4,09%

Groei

Revenue Growth (5Y)
3,01%
Revenue (1Y)-1,08%
Earnings (1Y)3,24%
FCF Growth (3Y)39,67%

Kwaliteit

Return on Equity
8,95%
ROIC6,40%
Net Margin15,79%
Op. Margin18,23%

Veiligheid

Debt / Equity
0,18
Current Ratio3,20
Interest Coverage9,56

Waardering

P/E Ratio
1,58
P/B Ratio0,14
EV/EBITDA-0,14
Dividend Yield0,04%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -1,08% Revenue Growth (3Y) -1,97%
Earnings Growth (1Y) 3,24% Earnings Growth (3Y) -13,53%
Revenue Growth (5Y) 3,01% Earnings Growth (5Y) -0,24%
Profitability
Revenue (TTM) 13,09B Net Income (TTM) 2,07B
ROE 8,95% ROA 5,95%
Gross Margin 50,28% Operating Margin 18,23%
Net Margin 15,79% Free Cash Flow (TTM) 2,14B
ROIC 6,40% FCF Growth (3Y) 39,67%
Safety
Debt / Equity 0,18 Current Ratio 3,20
Interest Coverage 9,56 Dividend Yield 0,04%
Valuation
P/E Ratio 1,58 P/B Ratio 0,14
P/S Ratio 0,25 PEG Ratio 2,36
EV/EBITDA -0,14 Dividend Yield 0,04%
Market Cap 3,26B Enterprise Value -326,77M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 13,09B 13,23B 13,62B 13,15B 11,62B
Net Income 2,07B 2,00B 2,76B 2,28B 2,09B
EPS (Diluted) 0,45 0,44 0,61 0,50 0,46
Gross Profit 6,58B 6,64B 7,31B 7,35B 6,46B
Operating Income 2,39B 2,30B 2,92B 2,89B 2,28B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 34,76B 33,67B 33,20B 30,37B 27,34B
Total Liabilities 9,42B 9,68B 9,75B 9,46B 8,95B
Shareholders' Equity 23,75B 22,45B 21,67B 19,27B 17,55B
Total Debt 4,19B 4,17B 4,49B 4,14B 4,32B
Cash & Equivalents 7,78B 6,99B 6,86B 6,63B 5,51B
Current Assets 19,44B 18,63B 18,29B 16,26B 14,37B
Current Liabilities 6,08B 7,58B 5,93B 5,18B 4,50B

Strategiescores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#333 of 820
48
Value Defensive Investing (Benjamin Graham)
#177 of 708
44

Recente Activiteit

Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt Defensive Investing (Benjamin Graham)
Mar 24, 2026